BNF_04

The controlled drugs bulletin and resources have been written to support CCG teams that have a role in supporting the regional NHS England Controlled Drugs Accountable Officer (CDAO).  An audit ...
Created on 02 February 2017
Due to concerns over hypnotic dependence, hypnotic prescribing has been subject to scrutiny and review for a number of years. In this bulletin, we offer advice on managing new patients with insomnia, recommend ...
This bulletin and associated resources support medicines optimisation in non neuropathic (non cancer) pain.  It looks at the place in therapy of different pain treatments and also helps identify where ...
Created on 14 November 2016
These resources support the appropriate prescribing and review of ADHD treatments including initiation and monitoring of treatment. An audit is available to support identification of patients needing a ...
This bulletin reviews the place in therapy of unlicensed buccal midazolam and switching to a licences product where appropriate. Safety issues and savings are also discussed.   Buccal midazolam ...
Created on 17 August 2016
This Antipsychotics bulletin and resources have been updated to include cost effective choices of modified release quetiapine products (for those organisations wishing to use branded generic prescribing). ...
Immediate release fentanyl has a NICE do not do as a first line treatment for breakthrough pain. This bulletin which is a DROP list support bulletin will focus on fentanyl immediate-release formulations ...
These resources review the place in therapy of dosulepin which is listed as a NICE 'do not do'. The drug has a very small margin of safety between the maximum therapeutic dose and potentially fatal ...
Created on 27 January 2016
This bulletin is an update of Bulletin 50 on neuropathic pain. It reviews the place in therapy of neuropathic pain treatments and offers guidance and support material for organisations considering ...
The guidelines on the management of controlled drugs in care homes has been updated to reflect changes in the Safer Management of Controlled Drugs Regulations and also provide more clarity in the bulletin ...
As a new part of our growing Self Care Webkit - we're pleased to launch two new implementation, or campaign, packs for B89: Analgesia-pain and fever and  B94: Coughs and colds. These campaign packs ...
The controlled drugs good practice guide is a guide for care homes to use (and adapt into a local policy if they wish to do so) to ensure that the handling, administration, and disposal of controlled ...
Created on 25 September 2014
The opioid patches bulletin focuses on the safe and appropriate prescribing of opioid patches as well as cost effective treatment choices. An audit is available to help support the review of patients ...
This bulletin has been written as an implementation guide for MHRA guidance on which anti epileptic drugs can be switched. Tools are provided to support organisations considering a generic switch for appropriate ...
We're pleased to release the 6 month update to the Data pack that accompanies Bulletin 52 - Oxycodone MR.   Oxycodone MR
In addition to now releasing a data pack with each new bulletin, the PrescQIPP team now updates each data pack every six months. We are now pleased to release the first update to our Pregabalin in neuropathic ...
Created on 12 February 2014
This bulletin is no. 15 on the PrescQIPP DROP-List and focuses on Tramacet® (paracetamol 325mg/tramadol 37.5mg) and provides the rationale for new patients to be initiated on paracetamol or paracetamol ...
Across the PrescQIPP membership (approximately 16.4 million patients) over £60 million is spent annually on pregabalin (ePACT May 2013). This bulletin reviews the place in therapy of neuropathic ...
This bulletin reviews the place in therapy of oxycodone MR and offers guidance and support material for organisations considering reviewing oxycodone MR prescribing as a QIPP project. The ...
This new bulletin looks at lidocaine plasters and provides the rationale for not initiating lidocaine plasters in new patients, and for current patients to be considered for discontinuation of ...